Vivo Bio Tech Ltd
Incorporated in 1987, Vivo Bio Tech Ltd is a supplier of SPF lab animals and is a breeder
& distributor of rodent models.
- Market Cap ₹ 57.5 Cr.
- Current Price ₹ 38.6
- High / Low ₹ 56.0 / 30.8
- Stock P/E 7.65
- Book Value ₹ 40.2
- Dividend Yield 0.00 %
- ROCE 10.1 %
- ROE 4.74 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.96 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.27% over past five years.
- Company has a low return on equity of 5.03% over last 3 years.
- Working capital days have increased from 218 days to 328 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
14.37 | 16.13 | 17.79 | 28.58 | 34.13 | 47.00 | 55.83 | 55.35 | 51.78 | 51.39 | 51.62 | 44.88 | 46.43 | |
12.01 | 14.38 | 14.99 | 24.87 | 26.50 | 36.11 | 46.32 | 42.87 | 33.98 | 35.30 | 29.80 | 23.62 | 24.68 | |
Operating Profit | 2.36 | 1.75 | 2.80 | 3.71 | 7.63 | 10.89 | 9.51 | 12.48 | 17.80 | 16.09 | 21.82 | 21.26 | 21.75 |
OPM % | 16.42% | 10.85% | 15.74% | 12.98% | 22.36% | 23.17% | 17.03% | 22.55% | 34.38% | 31.31% | 42.27% | 47.37% | 46.84% |
0.76 | 0.88 | 0.95 | 0.89 | 0.40 | 0.13 | 0.01 | 0.05 | 0.08 | 0.09 | 0.04 | 0.04 | 4.68 | |
Interest | 0.78 | 0.39 | 0.51 | 0.47 | 1.29 | 2.37 | 2.64 | 3.10 | 3.67 | 4.27 | 7.99 | 7.95 | 7.72 |
Depreciation | 1.57 | 1.56 | 3.05 | 3.35 | 3.90 | 4.64 | 5.06 | 5.17 | 5.59 | 7.44 | 9.27 | 9.29 | 9.23 |
Profit before tax | 0.77 | 0.68 | 0.19 | 0.78 | 2.84 | 4.01 | 1.82 | 4.26 | 8.62 | 4.47 | 4.60 | 4.06 | 9.48 |
Tax % | 49.35% | 55.88% | -142.11% | -16.67% | 11.62% | 21.95% | -23.08% | -4.46% | 34.11% | 50.78% | 42.83% | 37.93% | |
0.39 | 0.29 | 0.46 | 0.91 | 2.50 | 3.12 | 2.25 | 4.44 | 5.68 | 2.20 | 2.63 | 2.52 | 7.51 | |
EPS in Rs | 0.42 | 0.31 | 0.49 | 0.97 | 2.67 | 3.17 | 1.82 | 3.45 | 4.23 | 1.54 | 1.76 | 1.69 | 5.04 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | -4% |
3 Years: | -5% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 2% |
3 Years: | -24% |
TTM: | 177% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | -15% |
1 Year: | 15% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 5% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 | 9.85 | 12.35 | 12.89 | 13.42 | 14.26 | 14.90 | 14.90 | 14.90 |
Reserves | -1.12 | -0.82 | -0.18 | 0.73 | 3.25 | 7.38 | 14.63 | 20.15 | 27.70 | 32.19 | 36.97 | 39.49 | 44.98 |
3.58 | 6.62 | 5.69 | 16.91 | 27.06 | 25.11 | 21.67 | 22.09 | 28.73 | 65.24 | 60.17 | 70.84 | 55.66 | |
26.86 | 24.89 | 26.57 | 18.68 | 11.47 | 17.19 | 6.66 | 6.29 | 7.46 | 8.61 | 8.77 | 9.57 | 10.24 | |
Total Liabilities | 38.67 | 40.04 | 41.43 | 45.67 | 51.13 | 59.53 | 55.31 | 61.42 | 77.31 | 120.30 | 120.81 | 134.80 | 125.78 |
20.60 | 20.47 | 19.57 | 23.35 | 28.37 | 27.47 | 29.82 | 31.63 | 48.69 | 91.81 | 85.51 | 77.01 | 70.90 | |
CWIP | 0.00 | 0.00 | 0.07 | 0.04 | 2.96 | 3.94 | 0.07 | 0.15 | 0.32 | 0.87 | 1.90 | 9.21 | 11.30 |
Investments | 0.14 | 0.14 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
17.93 | 19.43 | 21.77 | 22.25 | 19.77 | 28.09 | 25.39 | 29.60 | 28.26 | 27.58 | 33.36 | 48.54 | 43.54 | |
Total Assets | 38.67 | 40.04 | 41.43 | 45.67 | 51.13 | 59.53 | 55.31 | 61.42 | 77.31 | 120.30 | 120.81 | 134.80 | 125.78 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2.13 | 2.79 | 2.13 | 8.73 | -5.65 | 11.11 | -0.79 | 7.72 | 14.10 | 16.43 | 14.73 | 15.83 | |
25.03 | -1.42 | -1.92 | -7.12 | -11.84 | -4.72 | -3.53 | -7.08 | -22.82 | -51.11 | -4.00 | -7.95 | |
-19.33 | -0.44 | -0.89 | -0.32 | 6.83 | -3.43 | 0.70 | -0.18 | 8.83 | 35.04 | -11.20 | -7.56 | |
Net Cash Flow | 7.83 | 0.93 | -0.68 | 1.29 | -10.67 | 2.96 | -3.62 | 0.46 | 0.11 | 0.37 | -0.47 | 0.32 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 102.36 | 97.30 | 88.43 | 48.79 | 82.03 | 91.48 | 54.98 | 69.11 | 51.39 | 85.37 | 87.54 | 92.47 |
Inventory Days | 3.92 | 42.06 | 557.61 | 169.23 | 204.47 | 289.48 | 255.75 | 451.13 | 672.29 | 312.99 | 429.70 | 831.44 |
Days Payable | 857.55 | 1,160.13 | 814.41 | 362.93 | 242.14 | 304.36 | 152.08 | 166.72 | 70.37 | 74.02 | 50.68 | 100.49 |
Cash Conversion Cycle | -751.27 | -1,020.76 | -168.38 | -144.91 | 44.36 | 76.61 | 158.65 | 353.52 | 653.31 | 324.35 | 466.56 | 823.42 |
Working Capital Days | -456.69 | -343.05 | -289.50 | -92.85 | 86.73 | 75.17 | 121.14 | 139.21 | 152.19 | 141.27 | 185.40 | 328.32 |
ROCE % | 7.82% | 7.94% | 4.67% | 5.97% | 12.39% | 15.56% | 9.80% | 14.18% | 19.67% | 9.63% | 11.25% | 10.12% |
Documents
Announcements
-
Board Meeting Outcome for Meeting Held Today, I.E. Thursday, November 21, 2024
21 Nov - Approval of Vivo Bio Employees Stock Option Scheme, 2024.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Nov
-
Board Meeting Intimation for Meeting To Be Held On Thursday, November 21, 2024.
15 Nov - Board meeting to approve employee stock option scheme.
-
Board Meeting Outcome for Outcome Of The Board Meeting
14 Nov - Approved un-audited financial results for Q2 FY2024.
- Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024 14 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Vivo Bio Tech is a full-service CRO offering
drug development & discovery services
to pharmaceutical & biotech companies.
The company provides both regulatory and
non-regulatory IND-enabling preclinical development services, screening and evaluating molecules for various pharmacological & therapeutic properties. Specifically for oncology,
the company provides design & development
of syngeneic/xenograft models for evaluation
of anti-cancer agents. Further, the company can customize In vivo DMPK studies to help profile drug candidates in both rodent and non-rodent animal models.